2005 年至 2016 年间，在门诊接受透析治疗的终末期肾病患者的医疗保险参保情况。
Medicare Enrollment Among Patients With End-Stage Kidney Disease Receiving Dialysis in Outpatient Facilities Between 2005 and 2016.
机构信息
Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.
Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
出版信息
JAMA. 2020 Apr 7;323(13):1314-1316. doi: 10.1001/jama.2020.0704.
Abstract
This study characterizes annual changes in enrollment of Medicare and non-Medicare patients treated at dialysis facilities before and after 2011 payment reforms and 2014 Affordable Care Act changes that influenced reimbursements.
摘要
本研究描述了在 2011 年支付改革和 2014 年《平价医疗法案》影响报销的改革之前和之后，在透析中心接受治疗的医疗保险和非医疗保险患者的年度入组变化情况。
相似文献
1
Medicare Enrollment Among Patients With End-Stage Kidney Disease Receiving Dialysis in Outpatient Facilities Between 2005 and 2016.2005 年至 2016 年间，在门诊接受透析治疗的终末期肾病患者的医疗保险参保情况。
JAMA. 2020 Apr 7;323(13):1314-1316. doi: 10.1001/jama.2020.0704.
2
Toward Antiracist Reimbursement Policy in End-Stage Kidney Disease: From Equality to Equity.迈向终末期肾病的反种族主义报销政策：从平等到公平
J Am Soc Nephrol. 2021 Oct;32(10):2422-2424. doi: 10.1681/ASN.2021020189. Epub 2021 Jul 12.
3
Proposed conditions for coverage directed toward dialysis facilities.针对透析设施提出的覆盖条件。
Health Care Law Mon. 2005 Apr:3-11.
4
Medicare program; end-stage renal disease prospective payment system. Final rule.医疗保险计划；终末期肾病前瞻性支付系统。最终规则。
Fed Regist. 2010 Aug 12;75(155):49029-214.
5
Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.美国慢性透析患者在医疗保险终末期肾病（ESRD）报销系统及促红细胞生成素（ESA）标签变更期间的红细胞（RBC）输血率。
BMC Nephrol. 2014 Jul 11;15:116. doi: 10.1186/1471-2369-15-116.
6
Bundled payment for ESRD--including ESAs in Medicare's dialysis package.终末期肾病的捆绑支付——医疗保险透析套餐中包括促红细胞生成素类似物。
N Engl J Med. 2011 Feb 17;364(7):593-5. doi: 10.1056/NEJMp1014187.
7
Impact of capitation on free-standing dialysis facilities: can you survive?按人头付费对独立透析机构的影响：你能生存下去吗？
Am J Kidney Dis. 1997 Oct;30(4):542-8. doi: 10.1016/s0272-6386(97)90314-0.
8
9
Understanding financial risk models: Implicationsfor nephrology practices and dialysis centers.理解金融风险模型：对肾脏病医疗实践及透析中心的影响
Nephrol News Issues. 2016 Mar;30(3):26-8, 30-3.
10
What can we expect down the road?
Nephrol News Issues. 2011 Apr;25(4):28-9.
引用本文的文献
1
Medicare Enrollment and Spending Among Patients Initiating Dialysis After the Affordable Care Act.《平价医疗法案》实施后开始透析的患者的医疗保险参保情况及支出
JAMA Health Forum. 2024 Dec 6;5(12):e244304. doi: 10.1001/jamahealthforum.2024.4304.
2
Expanding Access to High KDPI Kidney Transplant for Recipients Aged 60 y and Older: Cost Utility and Survival.扩大60岁及以上受者获得高分辨率肾移植的机会：成本效用与生存率
Transplant Direct. 2024 May 15;10(6):e1629. doi: 10.1097/TXD.0000000000001629. eCollection 2024 Jun.
3
The Association of Dialysis Facility Payer Mix With Access to Kidney Transplantation.透析设施支付方组合与获得肾移植机会的关联。
JAMA Netw Open. 2023 Jul 3;6(7):e2322803. doi: 10.1001/jamanetworkopen.2023.22803.
4
Assessment of Spending for Patients Initiating Dialysis Care.评估开始透析治疗的患者的支出。
JAMA Netw Open. 2022 Oct 3;5(10):e2239131. doi: 10.1001/jamanetworkopen.2022.39131.
5
Rates of Medicare Enrollment Among Dialysis Patients After Implementation of Medicare Payment Reform and the Affordable Care Act Marketplace.医疗保险支付改革和平价医疗法案市场实施后透析患者的医疗保险参保率。
JAMA Netw Open. 2022 Sep 1;5(9):e2232118. doi: 10.1001/jamanetworkopen.2022.32118.
6
Trends in Dialysis Industry Consolidation After Medicare Payment Reform, 2006-2016.2006-2016 年医疗保险支付改革后透析行业整合趋势。
JAMA Health Forum. 2021 Nov 5;2(11):e213626. doi: 10.1001/jamahealthforum.2021.3626. eCollection 2021 Nov.
本文引用的文献
1
Trends in Peritoneal Dialysis Use in the United States after Medicare Payment Reform.美国医疗保险支付改革后腹膜透析使用趋势。
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1763-1772. doi: 10.2215/CJN.05910519. Epub 2019 Nov 21.
Zotero 插件